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Abstract
Background: Disruptions in thalamic functional connectivity have been observed in people with schizophrenia and
in youth at clinical high risk (CHR) of psychosis. However, the impact of environmental risk factors for psychosis on
thalamic dysconnectivity is poorly understood. We tested whether thalamic dysconnectivity is related to patterns of
cannabis use in a CHR sample.
Methods: 162 CHR and 105 control participants were assessed on cannabis use severity, frequency, and age at
onset of first use as part of the North American Prodrome Longitudinal Study and completed resting-state fMRI
scans. Whole-brain thalamic functional connectivity maps were generated using individual subjects’ anatomically
defined thalamic seeds.
Results: Thalamic connectivity did not significantly correlate with current cannabis use severity or frequency in
either CHR or controls. In CHR cannabis users, a significant correlation emerged between attenuated thalamic
connectivity with left sensory/motor cortex and a younger age at onset of cannabis use. CHR who used cannabis
before age 15 did not differ on thalamic connectivity as compared to CHR who used after age 15 or CHR who
were cannabis naïve. No group differences in thalamic connectivity emerged when comparing CHR separated by
moderate/high use frequency, low-frequency or cannabis naïve.
Conclusions: Although a younger age at onset of cannabis use may be associated with disrupted thalamo-cortical
coupling, cannabis use does not appear to be an identifying characteristic for thalamic connectivity in CHR
with moderate/high use frequency compared to low-frequency users or CHR who are cannabis naïve.
Keywords: Cannabis, Clinical high risk, Functional connectivity, Resting state functional magnetic resonance
imaging, Psychosis, Schizophrenia, Thalamus
Background
Schizophrenia is a neurodevelopmental disorder charac-
terized by disturbed connectivity between components
of large-scale brain networks [1]. One of the most pro-
foundly altered neural systems involves thalamo-cortical
networks, which have been characterized by hypo-con-
nectivity between the thalamus and prefrontal cortex
(PFC) [2] and cerebellum [3, 4], and thalamic hyper-
connectivity with somatosensory and motor areas [2,
3, 5, 6]. A very recent study [7] in CHR youth ob-
served a pattern of thalamic dysconnectivity similar to
that seen in schizophrenia, that was more severe in
those who later converted to schizophrenia. In
addition, both patterns of thalamic dysconnectivity
significantly correlated with attenuated positive symp-
tom severity. This series of reports suggests that aber-
rant thalamic modulation of information to and from
cortical foci occurs prior to the onset of psychosis
and may in part underlie the pathophysiology of
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psychotic illnesses. However, the degree to which these
functional brain alterations are impacted by well-known
risk factors for psychosis is poorly understood.
Cannabis use is one environmental factor that is
known to modify the risk for psychosis. It is the most
widely used illicit substance in schizophrenia and its
risk states [8], and epidemiological data suggests a
role for cannabis in the onset of psychosis [9–12]. Re-
cent prospective data in youth at CHR for psychosis
has indicated that, among lifetime cannabis users,
higher baseline use severity [13] and frequency [14],
and first use before the age of 15 [14, 15] are all
associated with an increase in conversion to psych-
osis. Although no studies have evaluated the relation
between cannabis use patterns and functional con-
nectivity in CHR, two studies have reported thalamic
volume loss in association with cannabis use in youth
at genetic high risk of schizophrenia. One study re-
ported that frequent cannabis use was associated with
third ventricle enlargement, likely reflecting gray mat-
ter loss in the adjacent anterior medial region of the
thalamus [16]. This research group later published 2-year
longitudinal data showing that cannabis exposed indi-
viduals at genetic high risk of schizophrenia showed
bilateral thalamic volume loss compared to a non-
exposed group [17]. Given that cannabis use is known
to impact longitudinal thalamic structure in people
with a genetic high risk for schizophrenia, this raises
the question about the impact of cannabis use patterns
on thalamic functional connectivity in high risk sam-
ples. The relationship between thalamic neural circuitry
with prefrontal and cerebellar regions and cannabis use
may be particularly relevant, as post-mortem studies
have identified these regions as being rich in cannabinoid
(CB1) receptors [18].
In summary, the research to date suggests that thal-
amic functional abnormalities are present in schizo-
phrenia and its risk states, that thalamic structure is
impacted by lifetime cannabis use exposure and fre-
quency in high risk samples, and that early age of
first use and greater use severity and frequency
heighten the risk for psychosis. In a prior study in
the current sample [7], resting state functional mag-
netic resonance imaging (rs-fMRI) thalamic connectiv-
ity analyses revealed 5 regional clusters that showed
abnormal connectivity in CHR individuals relative to
healthy controls: lateral PFC, anterior cingulate gyrus,
cerebellum, and left and right sensory/motor cortices.
These regions share topographically organized recip-
rocal connections with the thalamus, are rich in CB1
receptors (see above), and have been linked to struc-
tural alterations in cannabis users (see above). There-
fore, in the current study we tested the hypotheses
that in individuals at CHR for psychosis, thalamic
dysconnectivity in these previously identified [7] regional
clusters are associated with 1) severity and frequency of
cannabis use, 2) age at onset of cannabis use, 3) current
cannabis use vs. no use, 4) early-onset cannabis use (i.e.
first use before age 15) compared to late-onset use (first
use at or after age 15), cannabis naïve CHR and con-
trols, and 5) cannabis use in CHR high-frequency users
compared to moderate- or low-frequency users, CHR
who are abstinent, and controls. If such links were
established, it could provide evidence that CHR youth
are indeed particularly vulnerable to the brain struc-
tural and functional consequences of cannabis use.
Methods
Participants
All participants were recruited as part of the multi-
site North American Prodrome Longitudinal Study
(NAPLS 2) [20], which was established to investigate
predictors and mechanisms of conversion to psych-
osis. The final NAPLS sample consists of 764 CHR
participants and 280 healthy controls. This paper re-
ports on the 162 CHR and 105 healthy controls who
provided baseline resting-state fMRI scans and also
completed a detailed baseline assessment on cannabis
use. All CHR participants were required to meet the
Criteria of Prodromal Syndromes (COPS) using the
Structured Interview for Prodromal-Risk Syndromes
(SIPS) [21]. Participants were excluded if they met
criteria for any current or lifetime axis I psychotic dis-
order, IQ < 70, past or current history of central nervous
system disorder or DSM-IV criteria for current sub-
stance dependence disorder. Control participants were
also excluded if they had a first degree relative with a
current or past psychotic disorder. We made every at-
tempt to match groups on age, sex and parental so-
cioeconomic status. A more detailed description of
ascertainment, inclusion and exclusion criteria, and
participant details is provided elsewhere [20].
Measures
The SIPS and the Scale of Prodromal Symptoms (SOPS)
[21] were used to assess criteria for a prodromal syn-
drome and severity of attenuated positive symptoms.
Post-training agreement on determining the prodromal
diagnoses was excellent (kappa = 0.90) [20].
Cannabis and other drug use was rated with the Alcohol
and Drug Use Scale [22] which records severity (1 = ab-
stinent, 2 = use without impairment, 3 = abuse, 4 = de-
pendence) and frequency of use (0 = no use, 1 = once or
twice per month, 2 = 3-4 times per month, 3 = 1–2 times
per week, 4 = 3–4 times per week, 5 = almost daily) in the
last month. Based on commonly used measures and inter-
view questions in the literature [12, 15, 23] we also
enquired the age at which cannabis was first used.
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Cannabis groups
Given evidence that first cannabis use before the age of
15 confers greater risk for conversion to psychosis
[14, 15], we separated CHR participants into three
groups of cannabis users: early-onset (cannabis use
before age 15), late-onset (cannabis use after age 15),
and cannabis naïve (had never used cannabis).
Secondly, given evidence that higher cannabis use
frequency confers greater risk for psychosis [14], par-
ticipants were separated into four groups according to
their frequency of cannabis use: high-frequency (i.e. daily
users), moderate-frequency (1–4 times per week), low-
frequency (1–4 times per month) and abstinent. How-
ever, only one CHR subject was using daily (see
Table 1); therefore this individual was combined with
the moderate-frequency group to form a moderate/
high-frequency group.
Neuroimaging data acquisition
Scanning was performed at eight sites. Five sites (UCLA,
Emory, Harvard, UNC, and Yale) used Siemens-Trio 3 T
scanners, two sites (Zucker-Hillside Hospital and UCSD)
used GE HDx scanners, and one site (Calgary) used a
GE Discovery scanner. Previously, we reported on results
in which 8 subjects each travelled to all 8 NAPLS-2 sites
and were scanned twice on successive days [24]. Results
indicated that site-related variations were trivial across
scanners, suggesting that neuroimaging can be per-
formed across multiple sites at the same level of reliabil-
ity as at a single site. All neuroimaging and functional
connectivity analyses followed prior work and best prac-
tices in the clinical connectivity literature with details
presented in Additional file 1.
Seed-based functional connectivity analysis (rs-fcMRI)
based on thalamic anatomy
Our seed-based fcMRI approach followed prior studies
using anatomically-defined thalamic seeds [25]. In-house
Matlab tools [26, 27] were used to examine thalamus
coupling with all gray matter voxels. We computed a
seed-based thalamus correlation map by extracting aver-
age time-series across all voxels in each subject’s bilateral
thalamus anatomically defined through Freesurfer-based
segmentation [28, 29]. This entire thalamic signal was
then correlated with each gray matter voxel, and the
computed Pearson correlation values were transformed
to z-scores using a Fisher r-to-Z transform, providing a
map for each subject that were entered into 2nd-level
analyses where each voxel’s value represented its connect-
ivity with the whole thalamus. We restricted analyses to
five regions that revealed robust thalamic dysconnectiv-
ity in a sample of chronic SCZ patients [30] and that
were similarly abnormal when identified using a priori
thalamic masks in the NAPLS-2 sample of CHR youth
[7] whose data are further analyzed in the current
study: right lateral PFC, anterior cingulate gyrus, cere-
bellum, and left and right sensory/motor cortices, as
shown in Figure 1a and 1b of reference [7]. Regional
coordinates are shown in Table 2. The r-to-z trans-
formed values were averaged across all voxels within
each of these regions.
Statistical analysis
Chi-square analyses for categorical variables and t-tests
for continuous variables were used to compare CHR and
control groups on demographics. To evaluate the impact
of confounding variables, Spearman correlations were
used to evaluate the relationship between thalamic vol-
umes and functional connectivity and age, alcohol use
and tobacco use. Variables that significantly correlated
with thalamic connectivity were entered as covariates in
subsequent analyses. Specifically, partial correlations
Table 1 Demographic and clinical characteristics of the CHR
and healthy control groups
CHR n = 162 HC n = 105
n (%) n (%) χ 2 p-value
Sex
Male 96 (59) 57 (54) 0.62 0.43
Female 66 (41) 48 (46)
Race
First Nations 2 (1) 2 (2) 10.1 0.26
Asian 9 (6) 10 (10)
Black 35 (22) 28 (27)
Latin America/Middle
East/White
93 (57) 59 (55)
Inter-racial 23 (14) 6 (6)
AUS/DUS cannabis use
frequency
Abstinent 112 (69) 92 (88) 17.1 0.004
1–4 times per month 26 (16) 11 (10)
1–4 times per week 21 (13) 2 (2)
Almost daily 3 (2) 0 (0)
AUS/DUS cannabis
use severity
Abstinent 116 (72) 92 (88) 11.7 0.003
Use without
impairment
37 (23) 13 (12)
Abuse 9 (6) 0 (0)
Mean (SD) Mean (SD) t p-value
Age (years) 19.4 (4.21) 19.5 (4.62) 0.25 0.80
Education (years) 11.8 (2.50) 12.7 (3.46) 2.32 0.02
Age at onset of
cannabis use (years)a
16.1 (3.20) 16.0 (2.30) 0.25 0.81
Note. CHR Clinical High Risk, HC Healthy Controls, SD Standard Deviation
aInformation on age of onset of cannabis use was available for 99 CHR and 38
control participants
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were used to measure associations of cannabis use sever-
ity, frequency and age at onset of use with thalamic
functional connectivity. CHR early-onset, late-onset and
cannabis naïve groups were compared on thalamic con-
nectivity across all 5 regions using a two-way repeated
measures MANCOVA with regions as the dependent
measure and demographic and clinical variables as co-
variates. To follow-up on significant Group X Region
interaction effects, separate one-way ANOVAs were per-
formed with Tukey’s post-hoc tests to compare groups
where appropriate. All F-tests involving repeated meas-
ure factors were based on Wilks’ Lambda. Similarly,
two-way repeated measures MANCOVA was used to
compare CHR use frequency groups (moderate/high-fre-
quency, low-frequency, abstinent) on thalamic con-
nectivity with regions as the dependent variable and
demographic and clinical variables as covariates. To
follow-up on significant Group X Region interaction
effects, separate one-way ANOVAs were performed
with Tukey’s post-hoc test applied where appropriate.
The critical p-value was set to 0.01 following Bonferroni
correction for multiple comparisons for the five regions of
interest when conducting follow up tests on individual re-
gions. NAPLS participants who did not provide cannabis
ratings were not considered in any analyses. Statistical
analyses were conducted using SPSS 21.0.
Procedures
All eight sites involved in this longitudinal study of pre-
dictors of conversion to psychosis recruited CHR indi-
viduals. Raters were experienced research clinicians who
demonstrated adequate reliability at routine reliability
checks. Gold standard post-training agreement on the
critical threshold for determining initial eligibility based
on the SIPS was excellent (kappa = 0.90). The principal
investigator or clinical psychiatrist or psychologist at
each site conducted a comprehensive clinical assessment
to determine if entry criteria were met. JA chaired
weekly conference calls to review criteria for all individ-
uals admitted to the study. Clinical assessments that
included the Alcohol and Drug Use Scale (AUS/DUS)
and the SOPS were conducted at baseline.
Informed written consent was obtained from those
who met criteria and were judged fully competent to
give consent. Parental consent was obtained from par-
ents/guardians of participants who were under age 16.
Consent was a written consent signed by the participant,
study coordinator and witness. Participants receive a
copy of the consent. The participants in this study were
not patients, and they do not have a diagnosis. They are
young people who are presenting with signs that suggest
they may be at risk for developing psychosis. None of
the participants have symptoms that would lead to any
diagnosis of a DSM-IV psychotic disorder. All of the
participants have IQ > than 70. All participants were
reviewed with either a licenced psychiatrist or licensed
clinical psychologist at all of the sites. The study was
carried out in accordance with The Code of Ethics of the
World Medical Association (Declaration of Helsinki) for
experiments involving humans and approved by the
Institutional Review Boards of all eight NAPLS sites:
Emory: Emory Institutional review Board; Zucker Hillside:
North-Shore LIJ Health System Office of the Human
Research Protection Program; Yale: Yale University Hu-
man Investigations Committee; UCLA: UCLA Institu-
tional review Board; UCSD: UCSD Human Research
Protections Program; Calgary: University of Calgary Con-
joint Health Research Ethics Board; UNC: University of
North Carolina Biomedical IRB; Harvard: Committee on
Clinical Investigation.
Results
Demographics
Demographic, clinical and behavioral characteristics of
CHR and control subjects are summarized in Table 1.
Age significantly and positively correlated with thalamic
connectivity with the anterior cingulate cortex (p = 0.01)
but no other region of interest (all ps > 0.06). Males and
females did not differ on thalamic connectivity with any
region of interest (all ps > 0.47). Alcohol use severity
Table 2 Partial correlations between resting state thalamic networks and AUS/DUS rated cannabis use severity, frequency, and age
at onset of cannabis use in the CHR and healthy control groups
X Y Z Hemisphere Anatomical landmark Severity Frequency Age at onset of cannabis use
CHR HC CHR HC CHR HC
n = 162 n = 105 n = 162 n = 105 n = 99 n = 38
−31 −67 −43 Left Cerebellum 0.01 (0.96) 0.01 (0.99) −0.01 (0.89) 0.04 (0.83) 0.21 (0.04) 0.13 (0.47)
31 42 31 Right Lateral prefrontal cortex 0.09 (0.28) −0.16 (0.36) 0.14 (0.09) −0.23 (0.19) 0.18 (0.08) 0.11 (0.55)
2 21 36 Midline Anterior cingulate gyrus −0.03 (0.68) −0.08 (0.65) −0.04 (0.63) −0.08 (0.65) 0.16 (0.16) 0.20 (0.25)
−35 −23 58 Left Sensory/ motor cortex 0.03 (0.73) −0.06 (0.74) −0.02 (0.79) −0.07 (0.69) 0.26 (0.01) 0.10 (0.58)
19 −27 70 Right Sensory/ motor cortex 0.03 (0.75) 0.12 (0.50) −0.01 (0.87) 0.02 (0.91) 0.23 (0.03) 0.10 (0.59)
Note. AUS/DUS Alcohol and drug use scale. CHR Clinical high risk, HC healthy control. Age, alcohol use and tobacco use have been entered as covariates. Results
expressed as Pearson’s correlations with corresponding p-value in brackets. Significant results are bolded
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significantly and inversely correlated with thalamic con-
nectivity with anterior cingulate cortex (p = 0.04) but no
other region (all ps > 0.22). Tobacco use severity signifi-
cantly and positively correlated with thalmo-cerebellar
connectivity (p = 0.03) but no other region of interest
(all ps > 0.33). Therefore, age, alcohol use and tobacco
use were entered as covariates in all statistical analyses.
The CHR and control participants did not differ on
age, sex or ethnicity, however, controls had significantly
higher education. Groups did not differ on age at onset
of cannabis use, though CHR participants had signifi-
cantly higher severity and frequency of cannabis use.
Thalamic volumes did not significantly correlate with
thalamic connectivity with any region (all r’s < 0.05, all
p’s > 0.20).
Thalamic functional connectivity in relation to cannabis
use severity and frequency
To test hypothesis 2, we evaluated correlations between
thalamic connectivity and cannabis use severity and fre-
quency, controlling for age, tobacco and alcohol use.
These results are shown in Table 2. In CHR, no signifi-
cant correlations emerged between cannabis use severity
or frequency and thalamic connectivity in any region.
Similarly, in controls, no significant correlations were
observed between cannabis use severity or frequency
and thalamic functional connectivity.
Thalamic functional connectivity in relation to age at
onset of cannabis use
To test hypothesis 3, we examined correlations between
thalamic connectivity with age at onset of cannabis use
in CHR and controls, entering age, tobacco and alcohol
as covariates.
As shown in Table 2, in CHR a significant correl-
ation was seen between thalamic hyper-connectivity
with left sensory/motor cortex with a younger age at
onset of cannabis use. Trends toward hyper-connectivity
between the thalamus and right sensory motor cortex,
and thalamo-cerebellar hypo-connectivity, in association
with a younger age at onset of cannabis use were also
seen. In the control group, no significant correlations were
observed between age at onset of cannabis use and thal-
amic connectivity.
Thalamic functional connectivity in current cannabis users
compared to non-users
To test hypothesis 1, we evaluated the thalamic func-
tional connectivity in current cannabis users compared
to non-users using a two-way repeated measures MAN-
COVA with age, alcohol and tobacco as covariates. In
CHR, 46 were current users and 116 were not currently
using cannabis. The Group effect was non-significant,
F(1, 157) = 0.34, p = 0.56. The Group X Region
interaction was also non-significant, F(4, 154) = 1.11, p =
0.35, Wilkes Lambda = 0.97, indicating that CHR cur-
rently using cannabis did not differ from those currently
abstinent from cannabis on thalamic connectivity in any
region of interest.
In controls, 13 were current users and 92 were not
currently using cannabis. The two-way repeated mea-
sures MANCOVA indicated a non-significant Group
effect, F(1, 100) = 0.14, p = 0.91. The Group X Region
interaction was also non-significant, F(4, 97) = 0.84,
p = 0. 15, Wilkes Lambda = 0.97, indicating that controls
currently using cannabis did not differ from those cur-
rently abstinent from cannabis on thalamic connectivity in
any region of interest.
Early age at onset of cannabis use and thalamic
connectivity in CHR and controls
To test hypothesis 4, we evaluated the association
between age at onset of cannabis use and thalamic con-
nectivity in CHR and controls. Within the CHR group,
32 people had an early-onset use of cannabis, 67 had a
late-onset, and 61 were cannabis naïve. Demographic
and clinical characteristics of these groups are summa-
rized in Additional file 2. These groups significantly dif-
fered in age, education, SOPS total positive symptoms,
as well as current alcohol, tobacco and cannabis use se-
verity. Therefore, these variables were included as covar-
iates in the MANOVA.
When comparing these three CHR groups and controls
on thalamic network dysconnectivity, the two-way re-
peated measures MANOVA indicated a non-significant
Group effect, F(3, 254) = 0.62, p = 0.60. The Group X
Region interaction was also non-significant, F(12, 664.4) =
0.69, p = 0.76, Wilkes Lambda = 0.97.
Comparison of cannabis use frequency groups on
thalamic functional connectivity in CHR and controls
To test hypothesis 5, we evaluated thalamic connectiv-
ity as a function of cannabis use frequency groups in
CHR, and controls. Demographic and clinical charac-
teristics of these groups are summarized in Additional
file 3. Within the CHR group, 24 had moderate/high-
frequency cannabis use, 26 people had a low-frequency
use, and 112 were abstinent. These groups significantly
differed on sex, SOPS total positive symptoms, as well
as current alcohol, tobacco and cannabis use severity.
Therefore, these variables were included as covariates
in the MANOVA.
The two-way repeated measures MANOVA indicated
a non-significant Group effect, F(3, 258) = 0.80, p =
0.50. The Group X Region interaction effect was also
non-significant, F(12, 675.0) = 1.48, p = 0.13, Wilkes
Lambda = 0.93.
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Discussion
Schizophrenia and its risk states have been character-
ized by dysconnectivity in thalamic neural circuitry
[2–7]. However, the impact of cannabis use—one en-
vironmental factor thought to increase the risk for
psychosis—on thalamic connectivity remains unknown. In
the current study we used resting state fMRI to
characterize thalamic dysconnectivity in relation to pat-
terns of cannabis use in a CHR sample and relative to a
healthy control group. Results indicated that thalamic
connectivity did not significantly correlate with current
cannabis use severity or frequency in either group. A
younger age at onset of cannabis use was significantly cor-
related with thalamic hyper-connectivity with left sensory/
motor cortex in CHR participants, but not in controls.
CHR early-onset users, late-onset users and cannabis
naïve participants were indistinguishable on thalamic
neural circuitry. No group differences in thalamic con-
nectivity were seen between CHR separated by moderate/
high-frequency, low-frequency or abstinent. These results
indicate that although a younger age at onset of cannabis
use correlated with disruptions in thalamo-cortical con-
nectivity in CHR, in the group analyses, CHR early-onset
cannabis users showed similar patterns of connectivity to
both late-onset and cannabis naïve CHR. Moderate/high-
frequency of cannabis use does not appear to be an identi-
fying characteristic for thalamic connectivity in CHR.
The severity or frequency of current cannabis use did
not correlate with thalamic connectivity in our CHR or
control participants. Although no published studies have
reported on the neural correlates of current cannabis
use severity in a CHR sample, higher frequency of can-
nabis use over 1 year has been associated with decreased
PFC volumes in subjects with an at-risk mental state
[31]. Findings from a cross-sectional study in people
with a genetic risk of schizophrenia suggests that higher
cannabis use frequency correlated with greater 3rd ven-
tricular volumes [16]. Individuals with adolescent onset
schizophrenia who used cannabis three times a week for
at least 6 months have a documented widespread gray
matter density loss and decreased white matter struc-
tural connectivity as measured with diffusion tensor im-
aging [32]. Although the existing literature suggests that
people at genetic risk for schizophrenia and people with
schizophrenia are particularly vulnerable to brain vol-
ume loss with greater exposure to cannabis, the current
results suggest that in people at CHR of psychosis thal-
amic neural circuitry is not affected by higher severity or
usage rates of cannabis.
Perhaps the most novel finding is the significant cor-
relation that emerged between increased thalamic con-
nectivity with left sensory/motor cortex and a younger
age at onset of cannabis use in CHR participants. The
sensory/motor cortex is rich in CB1 receptors [33, 34]
and cannabis intake has been associated with volumet-
ric reductions in frontal or superior parietal cortices in
a CHR sample [31], and early-onset schizophrenia co-
hort [35] and in first-episode schizophrenia [36]. Longi-
tudinal data suggests that adolescent cannabis users
with schizophrenia and a comorbid cannabis use dis-
order show an atypical pattern of cortical development
over an 18-month period compared to schizophrenia
patients without a cannabis disorder [37]. Interestingly,
separating CHR participants into early-onset, late-onset
and naïve cohorts did not reveal an age-specific effect
of onset of cannabis use on thalamic connectivity. This
set of results may suggest that thalamic connectivity is im-
pacted by the age of exposure of cannabis in a linear fash-
ion rather than by exposure during a sensitive period in
development in people at CHR of psychosis. These results
also suggest that cannabis use before age 15 is not an
identifying characteristic for thalamic functional dyscon-
nectivity in CHR youth [7].
Current cannabis use did not appear to reflect on thal-
amic connectivity in our CHR or control samples. The
only other study to conduct a cross-sectional evaluation of
the neural correlates of lifetime cannabis use in a high risk
sample reported that genetic high risk individuals with
heavy lifetime cannabis use (i.e., ≥40 times across the life-
time) showed decreased total cortical thickness compared
to moderate users and those who were cannabis naïve
[38]. In first-episode schizophrenia, cannabis use has been
linked to decreased gray matter density in posterior cingu-
late cortex, an area high in CB1 receptor expression [36],
but not to cerebellar volumes [39], an area also dense in
CB1 receptors. Current cannabis use in people with an
at-risk mental state has also been linked to decreased vol-
umes of posterior as well as anterior cingulate cortices
[40]. Interestingly, two longitudinal studies of genetic high
risk samples have reported decreases in thalamic, superior
frontal and hippocampal volumes following exposure to
cannabis over a 2-year follow-up period [17, 41]. Lon-
gitudinal data in first-episode schizophrenia has indi-
cated cortical thinning in several regions known to
share topographic connections with the thalamus in-
cluding lateral PFC and anterior cingulate cortex [42],
in addition to accelerated gray matter volume loss
and ventricular enlargement [43], following exposure
to cannabis during a 5-year follow-up period. Taken
together, the literature suggests that people at CHR of
psychosis and people with schizophrenia may have a
particular sensitivity to brain tissue loss after exposure to
cannabis. However, the current findings indicate that in
CHR youth current cannabis use does not result in func-
tional dysconnectivity in thalamic circuits.
Evaluation of CHR with a moderate/high-frequency of
cannabis use compared to those with low-use frequency
and abstinent CHR indicated no differential effects of
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cannabis use frequency on thalamic connectivity. It should
be noted that our sample had only one high-frequency
user, precluding evaluation of the effects heavy canna-
bis use on thalamic neural circuitry. Recent work by
Smith et al. [44] demonstrated that former heavy cannabis
users (who were otherwise psychiatrically healthy) show
cannabis-related morphological differences in the thal-
amus that were consistent with and more pronounced in
schizophrenia subjects who were former heavy users.
Evaluation of thalamic connectivity in CHR heavy canna-
bis users may be more informative. The present results
suggest that thalamic dysconnectivities previously re-
ported in this population [7] do not reflect cannabis use
frequency patterns.
Several limitations should be noted. The ascertainment
of cannabis use relied on participants’ self-report, which
may be less reliable than collection of biologically based
measures such as urine toxology data. Details on cannabis
dosage were not collected and therefore their potential
impact on thalamic connectivity cannot be determined. It
should also be recognized that the current findings offer
little insight into the cellular processes that result in the
observed correlation between thalamo-cortical function
and age at onset of cannabis use. Furthermore, cortical re-
gions appear to be connected to distinct, non-overlapping
regions of the thalamus [2], and the current analysis did
not parcellate the thalamus into distinct nuclei. Although
the current study focused on the thalamus, both CHR and
chronic patients with schizophrenia have been character-
ized by alterations across striatal and cortical networks
[45–49], and the effects of cannabis use on connectivity in
these circuits has not been established. The striatum
may be particularly sensitive to cannabis use, as there
is some evidence for increased sensitivity to delta-9-
tetrahydrocannabinol, the main psychoactive ingredient
of cannabis, in striatal subregions in people at genetic high
risk for psychosis and in people with psychotic disorders
[50]. Also, it remains unknown whether thalamic connect-
ivity varies over time with cannabis consumption, and
there is some longitudinal data in genetic high risk sam-
ples indicating decreases in thalamic volumes following
exposure to cannabis over a 2 year period [17, 41]. In this
regard, longitudinal evaluation of thalamic connectivity
and its covariation with cannabis use patterns may also be
relevant in CHR samples. There is limited research on
cannabis use and brain structure and function in CHR
samples; therefore, replication is needed to determine
generalizability of the findings.
Conclusions
In summary, the current work found a significant correl-
ation between attenuated thalamo-cerebellar connectiv-
ity and a younger age at onset of cannabis use in our
CHR sample. CHR who used cannabis before age 15 did
not differ on thalamic connectivity as compared to CHR
who used after age 15 or CHR who were cannabis naïve.
No group differences in thalamic connectivity emerged
when comparing CHR moderate/high-frequency users to
low-frequency users or naïve CHR. These findings sug-
gest that a younger age at onset of cannabis use is asso-
ciated with disrupted coupling between the thalamus
and left sensory/motor cortex. However cannabis use
does not appear to be an identifying characteristic for
thalamic connectivity in CHR who used before age 15,
or in moderate/heavy users compared to low-frequency
users or those who are abstinent.
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